U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16ClN3O
Molecular Weight 313.782
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOXAPINE

SMILES

c1ccc2c(c1)N=C(c3cc(ccc3O2)Cl)N4CCNCC4

InChI

InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

HIDE SMILES / InChI
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

7.1487357E11
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

7.1487357E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.55 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
319 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.02 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Other AEs: Ataxia, Drowsiness...
Other AEs:
Ataxia (>1)
Drowsiness (14%)
Dry mouth (14%)
Constipation (12%)
Blurred vision (7%)
Anxiety (>1)
Insomnia (>1)
Nervousness (>1)
Nightmare (>1)
Restlessness (>1)
Palpitations (>1)
Tremor (>1)
Confusion (>1)
Excitement (>1)
Edema (>1)
Skin rash (>1)
Prolactin increased (>1)
Nausea (>1)
Dizziness (>1)
Headache (>1)
Fatigue (>1)
Weakness (>1)
Appetite excessive (>1)
Perspiration excessive (>1)
Accommodation disturbance (<1%)
Mydriasis (<1%)
Micturition disorder (<1%)
Urinary retention (<1%)
Nasal stuffiness (<1%)
Hypotension (<1%)
Hypertension (<1%)
Syncope (<1%)
Tachycardia (<1%)
Drug fever (<1%)
Urticaria (<1%)
Photosensitized (<1%)
Pruritus (<1%)
Vasculitis (<1%)
Hepatitis (<1%)
Tingling (<1%)
Tinnitus (<1%)
Disorientation (<1%)
Seizures (<1%)
Hypomania (<1%)
Numbness (<1%)
Incoordination (<1%)
Concentration impairment (<1%)
Hyperthermia (<1%)
Extrapyramidal symptoms (<1%)
Tardive dyskinesia (<1%)
Leukopenia (<1%)
Agranulocytosis (<1%)
Epigastric distress (<1%)
Vomiting (<1%)
Flatulence (<1%)
Abdominal pain (<1%)
Taste peculiar (<1%)
Diarrhea (<1%)
Impotence (<1%)
Menstrual irregularity (<1%)
Breast enlargement (<1%)
Inappropriate antidiuretic hormone secretion (<1%)
Galactorrhea (<1%)
Lacrimation (<1%)
Weight gain (<1%)
Weight loss (<1%)
Impaired liver function (<1%)
Painful ejaculation (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Constipation 12%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Drowsiness 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Dry mouth 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Blurred vision 7%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Abdominal pain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Accommodation disturbance <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Agranulocytosis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Breast enlargement <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Concentration impairment <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Diarrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Disorientation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Drug fever <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Epigastric distress <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Extrapyramidal symptoms <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Flatulence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Galactorrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hepatitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypertension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hyperthermia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypomania <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypotension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Impaired liver function <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Impotence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Inappropriate antidiuretic hormone secretion <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Incoordination <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Lacrimation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Leukopenia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Menstrual irregularity <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Micturition disorder <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Mydriasis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nasal stuffiness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Numbness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Painful ejaculation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Photosensitized <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Pruritus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Seizures <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Syncope <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tachycardia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tardive dyskinesia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Taste peculiar <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tingling <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tinnitus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Urinary retention <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Urticaria <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Vasculitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Vomiting <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weight gain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weight loss <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Anxiety >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Appetite excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Ataxia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Confusion >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Dizziness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Edema >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Excitement >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Fatigue >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Headache >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Insomnia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nausea >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nervousness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nightmare >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Palpitations >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Perspiration excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Prolactin increased >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Restlessness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Skin rash >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tremor >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weakness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Amoxapine-associated acute renal failure.
1985 Jun
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats.
1985 Oct
Amoxapine-induced extrapyramidal effects.
1986 Jun
Amoxapine-induced cognitive impairment in two patients.
1987 Apr
Acute myocardial failure following amoxapine intoxication.
1988 Feb
Biochemical evidence that high concentrations of the antidepressant amoxapine may cause inhibition of mitochondrial electron transport.
1988 Mar 30
The clinical pharmacology of depressive states.
2002 Mar
Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors.
2004
The pharmacological management of depression.
2005
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
2005 Dec
Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
2005 Jul-Aug
Submissive behavior in mice as a test for antidepressant drug activity.
2005 Oct
Use of antidepressant medications in relation to the incidence of breast cancer.
2006 Apr 10
[Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on].
2006 Aug
A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum.
2006 Feb
Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection.
2006 Feb
Risperidone in the treatment of psychotic depression.
2006 Jun
Novel two-stage screening procedure leads to the identification of a new class of transfection enhancers.
2006 Jun
Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method.
2006 Oct 16
Pharmacological properties of glycine uptake in the developing rat retina.
2006 Sep
Amoxapine as an antipsychotic: comparative study versus haloperidol.
2007 Dec
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs.
2007 Mar
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.
2007 May
Pharmacological causes of hyperprolactinemia.
2007 Oct
Effects of different antidepressant treatments on the core of depression.
2008
An autopsy case of poisoning with ethanol and psychotropic drugs.
2008 Apr
Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.
2008 Dec
Amoxapine-associated acute respiratory distress.
2008 Jan
Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography-mass spectrometry.
2008 Jul
Functional expression of the glycine transporter 1 on bullfrog retinal cones.
2008 Nov 19
Effectiveness of a multifactorial cardiovascular risk reduction clinic for diabetes patients with depression.
2008 Oct
Depression following thrombotic cardiovascular events in elderly medicare beneficiaries: risk of morbidity and mortality.
2009
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
Persistence and compliance to antidepressant treatment in patients with depression: a chart review.
2009 Jun 16
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Amoxapine-induced tardive dyskinesia.
2009 Oct-Dec
A new strategy for antidepressant prescription.
2010
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma.
2010 Dec
Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways.
2010 Feb
Hallucinations: Clinical aspects and management.
2010 Jan
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
2010 Jan
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.
2010 Jan
Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
2010 Mar
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data.
2010 May 17
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray.
2010 Nov 30
Tricyclic antidepressants and headaches: systematic review and meta-analysis.
2010 Oct 20
Refractory hypotension during general anaesthesia caused by the long-term use of amoxapine.
2010 Sep
Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.
2011
Patents

Sample Use Guides

Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration: Oral
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Name Type Language
AMOXAPINE
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMOXAPINE [USP MONOGRAPH]
Common Name English
AMOXAPINE [VANDF]
Common Name English
2-CHLORO-11-(1-PIPERAZINYL)DIBENZ(B,F)(1,4)OXAZEPINE
Systematic Name English
NSC-759559
Code English
CL-67,772
Code English
DIBENZ(B,F)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-
Systematic Name English
AMOXAPINE [INN]
Common Name English
AMOXAPINE [USP-RS]
Common Name English
CL 67772
Code English
AMOXAPINE [USP]
Common Name English
CL 67,772
Code English
LOXAPINE SUCCINATE IMPURITY, AMOXAPINE- [USP]
Common Name English
AMOXAPINE [MI]
Common Name English
AMOXAPINE [JAN]
Common Name English
AMOXAPINE [ORANGE BOOK]
Common Name English
ASENDIN
Brand Name English
AMOXAPINE [MART.]
Common Name English
AMOXAPINE [USAN]
Common Name English
CL-67772
Code English
Classification Tree Code System Code
WHO-VATC QN06AA17
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
NDF-RT N0000175752
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
WHO-ATC N06AA17
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
LIVERTOX 48
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
NCI_THESAURUS C94727
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
Code System Code Type Description
DRUG CENTRAL
191
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
EVMPD
SUB05479MIG
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
LACTMED
Amoxapine
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
RXCUI
722
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY RxNorm
FDA UNII
R63VQ857OT
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
CAS
14028-44-5
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
IUPHAR
201
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
MERCK INDEX
M1843
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
237-867-1
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
INN
3049
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
DRUG BANK
DB00543
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
USP_CATALOG
1031401
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY USP-RS
EPA CompTox
14028-44-5
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
WIKIPEDIA
Amoxapine
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
PUBCHEM
2170
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
MESH
D000657
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL1113
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
NCI_THESAURUS
C47397
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY